This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challe… Altro …
This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. The book is divided into 4 parts. The first part begins with the current technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. The second part deals with the use proteomics in cell signaling. At the present, the pharmaceutical and biotechnology industries have many potentially useful small molecule inhibitors of many pathways important in cancer that have yet to be taken to clinical trials. Understanding protein-protein interaction and posttranslational modifications through proteomics will likely make it much more feasible to do effective clinical trials of these small molecules alone and in combinations to overcome drug resistance and improve patient care. The third part of the book moves from signaling to actual clinical applications of proteomics in cancer therapy. Case studies in may tumor types are provided to show the feasibility of generating the critical information needed to individualization of therapy in cancer patients. The final part of the book provides in depth information on annotating the human proteome and the role of Food and Drug Administration (FDA) in regulating the use of proteomics in cancer therapy. To functionally annotate the human proteome, the Swiss Institute for Bioinformatics (SIB) and the European Bioinformatics Institute (EBI) initiated a major effort to distribute to the scientific community highly integrated information on human protein sequences. This initiative, which is called the Human Proteomics Initiative (HPI) aims to provide for each known human protein a wealth of information that include the description of its function, domain and protein family classification, subcellular location, posttranslational modifications, variants and similarities to other proteins. Integration of bioinformatics into clinical application of proteomics in cancer therapy is outlined as well as regulations and policy of commercial application of proteomics in patient care. Books > Biomedicine Soft cover, Springer Shop<
Springer.com
new in stock. Costi di spedizione:zzgl. Versandkosten. (EUR 0.00) Details...
(*) Libro esaurito significa che il libro non è attualmente disponibile in una qualsiasi delle piattaforme associate che di ricerca.
Paperback, [PU: Humana Press Inc.], It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in canc… Altro …
Paperback, [PU: Humana Press Inc.], It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics., Oncology<
BookDepository.com
Costi di spedizione:Versandkostenfrei. (EUR 0.00) Details...
(*) Libro esaurito significa che il libro non è attualmente disponibile in una qualsiasi delle piattaforme associate che di ricerca.
This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challe… Altro …
This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. The book is divided into 4 parts. The first part begins with the current technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. The second part deals with the use proteomics in cell signaling. At the present, the pharmaceutical and biotechnology industries have many potentially useful small molecule inhibitors of many pathways important in cancer that have yet to be taken to clinical trials. Understanding protein-protein interaction and posttranslational modifications through proteomics will likely make it much more feasible to do effective clinical trials of these small molecules alone and in combinations to overcome drug resistance and improve patient care. The third part of the book moves from signaling to actual clinical applications of proteomics in cancer therapy. Case studies in may tumor types are provided to show the feasibility of generating the critical information needed to individualization of therapy in cancer patients. The final part of the book provides in depth information on annotating the human proteome and the role of Food and Drug Administration (FDA) in regulating the use of proteomics in cancer therapy. To functionally annotate the human proteome, the Swiss Institute for Bioinformatics (SIB) and the European Bioinformatics Institute (EBI) initiated a major effort to distribute to the scientific community highly integrated information on human protein sequences. This initiative, which is called the Human Proteomics Initiative (HPI) aims to provide for each known human protein a wealth of information that include the description of its function, domain and protein family classification, subcellular location, posttranslational modifications, variants and similarities to other proteins. Integration of bioinformatics into clinical application of proteomics in cancer therapy is outlined as well as regulations and policy of commercial application of proteomics in patient care. Books > Biomedicine Soft cover, Springer Shop<
new in stock. Costi di spedizione:zzgl. Versandkosten. (EUR 0.00)
Paperback, [PU: Humana Press Inc.], It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in canc… Altro …
Paperback, [PU: Humana Press Inc.], It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics., Oncology<
- Costi di spedizione:Versandkostenfrei. (EUR 0.00)
1Poiché alcune piattaforme non trasmettono le condizioni di spedizione e queste possono dipendere dal paese di consegna, dal prezzo di acquisto, dal peso e dalle dimensioni dell'articolo, dall'eventuale iscrizione alla piattaforma, dalla consegna diretta da parte della piattaforma o tramite un fornitore terzo (Marketplace), ecc. è possibile che le spese di spedizione indicate da eurolibro non corrispondano a quelle della piattaforma offerente.
Dati bibliografici del miglior libro corrispondente
This book covers current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics.
Informazioni dettagliate del libro - Cancer Proteomics: From Bench to Bedside
EAN (ISBN-13): 9781617378072 ISBN (ISBN-10): 1617378070 Copertina rigida Copertina flessibile Anno di pubblicazione: 2010 Editore: SPRINGER VERLAG GMBH 276 Pagine Peso: 0,399 kg Lingua: eng/Englisch
Libro nella banca dati dal 2012-11-02T20:05:20+01:00 (Zurich) Pagina di dettaglio ultima modifica in 2021-09-19T17:24:38+02:00 (Zurich) ISBN/EAN: 9781617378072
ISBN - Stili di scrittura alternativi: 1-61737-807-0, 978-1-61737-807-2 Stili di scrittura alternativi e concetti di ricerca simili: Autore del libro : daoud
Dati dell'editore
Autore: Sayed S. Daoud Titolo: Cancer Drug Discovery and Development; Cancer Proteomics - From Bench to Bedside Editore: Humana; Humana Press 264 Pagine Anno di pubblicazione: 2010-12-09 Totowa; NJ; US Stampato / Fatto in Lingua: Inglese 219,99 € (DE)
BC; Hardcover, Softcover / Medizin/Nichtklinische Fächer; Onkologie; Verstehen; Bioinformatics; Cancer Research; Carcinom; Oncology; Proteomics; Translation; classification; diagnostics; proteins; Cancer Biology; Protein Biochemistry; Oncology; Biochemie; BB
Proteomics Technologies.- Current and Emerging Mass Spectrometry Instrumentation and Methods for Proteomic Analyses.- Cell Signaling Proteomics.- Integration of Genomics and Proteomics in Dissecting p53 Signaling.- Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy.- Tumor Proteomics.- Oncoproteomics for Personalized Management of Cancer.- Application of Serum and Tissue Proteomics to Understand and Detect Solid Tumors.- Insight on Renal Cell Carcinoma Proteome.- Proteomics in Lung Cancer.- Proteomic Strategies of Therapeutic Individualization and Target Discovery in Acute Myeloid Leukemia.- New Tumor Biomarkers.- Bioinformatics and Regulatory Aspects of Proteomics.- Annotating the Human Proteome.- Regulatory Issues in the Co-Development of Oncology Drugs and Proteomic Tests: An Overview.
Altri libri che potrebbero essere simili a questo:
